Literature DB >> 8759657

The prevalence of esophagitis in patients with duodenal ulcer or ulcer-like dyspepsia.

E J Boyd1.   

Abstract

OBJECTIVE: It has been reported that 30-72% of patients with duodenal ulcer disease also have esophagitis. However, many of these reports included patients who had severe or complicated ulcer disease, so that the high prevalence may reflect pyloric stenosis or gastric hyper-secretion. The objective of this study was to determine the prevalence of esophagitis in unselected patients with duodenal ulcer disease or ulcer-like dyspepsia.
METHOD: A prospective study of endoscopic and histological esophagitis in consecutive patients with either duodenal ulcer disease or with ulcer-like dyspepsia.
RESULTS: Of 27 patients with duodenal ulcer disease, 33% had endoscopic esophagitis, 26% had histological esophagitis, and 48% had esophagitis by either criterion. Of 66 patients with ulcer-like dyspepsia, 35% had endoscopic esophagitis, 47% had histological esophagitis, and 62% had esophagitis by either criterion. Esophagitis was independent of patients' Helicobacter pylori status.
CONCLUSIONS: Esophagitis is common in patients with duodenal ulcer disease, and the prevalence is similar in patients with ulcer-like dyspepsia. In addition to causing heartburn, esophagitis may also be cause ulcer-like epigastric pain. Concomitant esophagitis may account for the persisting or recurring dyspepsia that has been reported in up to one-third of duodenal ulcer patients after successful eradication of H. pylori.

Entities:  

Mesh:

Year:  1996        PMID: 8759657

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  16 in total

Review 1.  Gastro-oesophageal reflux disease and Helicobacter pylori: an intricate relation.

Authors:  D McNamara; C O'Morain
Journal:  Gut       Date:  1999-07       Impact factor: 23.059

2.  The phenotype of gastric mucosa coexisting with Barrett's oesophagus.

Authors:  M Rugge; V Russo; G Busatto; R M Genta; F Di Mario; F Farinati; D Y Graham
Journal:  J Clin Pathol       Date:  2001-06       Impact factor: 3.411

3.  The prevalence of Barrett's esophagus and erosive esophagitis in patients undergoing upper endoscopy for dyspepsia in a VA population.

Authors:  Michael J Connor; Allan P Weston; Matthew S Mayo; Prateek Sharma
Journal:  Dig Dis Sci       Date:  2004-06       Impact factor: 3.199

Review 4.  Helicobacter pylori in gastro-oesophageal reflux disease: causal agent, independent or protective factor?

Authors:  J Labenz; P Malfertheiner
Journal:  Gut       Date:  1997-09       Impact factor: 23.059

5.  Decision analysis of histamine H2-receptor antagonist maintenance therapy versus Helicobacter pylori eradication therapy: a randomised controlled trial in patients with continuing pain after duodenal ulcer.

Authors:  M Tavakoli; A T Prach; M Malek; D Hopwood; B W Senior; F E Murray
Journal:  Pharmacoeconomics       Date:  1999-10       Impact factor: 4.981

6.  The significance of cagA(+) Helicobacter pylori in reflux oesophagitis.

Authors:  V J Warburton-Timms; A Charlett; R M Valori; J S Uff; N A Shepherd; H Barr; C A McNulty
Journal:  Gut       Date:  2001-09       Impact factor: 23.059

Review 7.  Contemplating the future without Helicobacter pylori and the dire consequences hypothesis.

Authors:  David Y Graham; Yoshio Yamaoka; Hoda M Malaty
Journal:  Helicobacter       Date:  2007-11       Impact factor: 5.753

8.  Assessment of symptomatic response as predictor of Helicobacter pylori status following eradication therapy in patients with ulcer.

Authors:  K E McColl; A el-Nujumi; L S Murray; E M el-Omar; A Dickson; A W Kelman; T E Hilditch
Journal:  Gut       Date:  1998-05       Impact factor: 23.059

9.  The implications of Helicobacter pylori infection for gastroesophageal reflux disease: studies presented at Digestive Disease Week 2003.

Authors:  Benson T Massey
Journal:  Curr Gastroenterol Rep       Date:  2004-06

10.  Gastroesophageal reflux disease: medical or surgical treatment?

Authors:  Theodore Liakakos; George Karamanolis; Paul Patapis; Evangelos P Misiakos
Journal:  Gastroenterol Res Pract       Date:  2009-12-31       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.